Summary. Sera from a group of 79 patients with pernicious anemia were studied for the presence of antibody to intrinsic factor. Two general types of antibody activity were found, and it was possible to distinguish three groups of pernicious anemia sera on the basis of their content of these types.
Introduction
The presence of antibodies to intrinsic factor in the sera of patients with pernicious anemia is well established . Two general types of test have been used to detect the antibody activity against human intrinsic factor (IF) in vitro.
One type detects the ability of certain pernicious anemia sera to inhibit the binding of radioactive vitamin B12 (B12) by IF as demonstrated by dialysis (5) , gel filtration (5) , charcoal adsorption (6) , and zirconyl phosphate gel adsorption (7) techniques. These sera also inhibit IF-mediated absorption of B12 when IF, serum, and B,2 mixed in that sequence, are fed to a patient with pernicious anemia (5) . The second type of test detects the combination of antibody with IF-radioactive B12 (IF-B12) complex. This combination of antibody with IF-B12 may be demonstrated by electrophoretic (3) , coprecipitation (4, 9, 10), gel filtration (11) , and immunodiffusion techniques (12, 13) . Sera containing this antibody have been shown to inhibit IF-mediated B12 absorption when IF, Ban12, d serum, mixed in that sequence, are fed to a patient with pernicious anemia (3, 14, 15) . The sequences differ in that the antibody-containing serum is added to the IF before the B12 in the first sequence and after the B12 in the latter sequence.
For the purposes of this study, sera that block the binding of B12 by IF are said to contain antibody I activity, and sera that contain antibodies reactive with the IF-B12 complex are said to contain antibody II activity. Preliminary reports from this laboratory (11, 14, 15) and elsewhere (16) have indicated that these two activities are the result of the action of at least two different types of antibody molecules: one that will react with IF and block B12 binding, and one that will react with the IF-B12 complex. If The present study reports in vitro and in vivo observations on three of the four classes of pernicious anemia sera described above and confirms and extends previous reports on the existence and behavior of the two types of antibody activity associated with these sera.
This report describes our observations on in vitro testing for antibody activity to IF in sera from a group of 79 patients with pernicious anemia and reports the effects of different sera in two in vivo testing procedures. In one procedure, serum is added to IF before the addition of B12; in the other procedure, the serum is added after the B12.
Methods

) In vitro observations
Serum collected during the past 4 years from patients with pernicious anemia has been stored frozen and was thawed immediately before use. Three different tests were used to detect antibody to IF in these sera. The source of IF used in these tests was pepsin-inactivated neutralized normal human gastric juice collected and prepared as previously described (17) (4), a method we have found to be more sensitive and reproducible than precipitation with ammonium sulfate (9, 10) . Rabbit antihuman globulin serum (RAHG) was prepared by injecting rabbits with ethanol-fractionated and DEAE-separated human y-globulin. 1 The optimal quantity of this RAHG serum that will cause maximal precipitation of a given quantity of antibody II-IF-B1= was established by titration. The coprecipitation technique used was as follows:
A quantity of gastric juice with a B1,-binding capacity of about 70 ng per ml was mixed with an equal volume of B,2-57Co solution (100 ng per ml, SA 3 nc per ng) and the mixture dialyzed against running tap water for 48 hours. This was then further diluted with 1 vol of water. The content of gastric juice in the mix was then 1 part in 4 (vol/vol). To 0.05 ml of this mix was added 0.05 ml of the test serum and then 1.1 ml of saline. Two aliquots of 0.1 ml were withdrawn from the mix, and each was precipitated with 0.2 ml of the RAHG serum. The RAHG: serum ratio in the final mix equaled approximately 50: 1. The serum: gastric juice ratio was 4: 1. The centrifuged precipitate was washed once with saline and assayed for radioactivity.
2) In vivo observations
Experiments were performed to study the in vivo effect of different antibody-containing sera. The sera were grouped into two different classes: AbI designates those sera with only antibody I activity,2 and AbI,II designates those sera with both antibody I and II activity, as determined in vitro. These sera were then tested for the coprecipitation test plotted as picograms of B12-57Co precipitated is depicted in Figure 3 .
The distinction between positive and negative results is clear, and the results were recorded as being either positive or negative for the presence of antibody II. A diagrammatic summary of these results is tabulated in Table I .
Fifty-two sera were tested by both electrophoresis and coprecipitation; all 79 were tested by the coprecipitation technique. The electrophoretic test with a SD of 6.5%o.
gave a negative result in three instances and a questionably positive result in five instances when the coprecipitation test gave a clearly positive result. This is probably due to two factors: 1) The electrophoretic test was performed with a serum: gastric juice ratio of 1: 1, whereas the coprecipitation test was performed with a serum:gastric juice ratio of 4:1; and 2) the electrophoretic retention test was at times difficult to interpret because of small amounts of radioactivity left at the origin when normal control serum was used.
Fifteen sera were found that had only antibody I activity at a 4:1 ratio of serum to gastric juice. No sera were found with only antibody II activity, although there was one serum with no detectable antibody I activity when tested at a serum:-gastric juice ratio of 1: 1, whereas antibody II was easily detectable at that ratio. The data are summarized in Figure 4 . AbIII sera inhibit IF-mediated B1y absorption when added to IF either before B12 or after B12.
It was conceivable that the data from the first set of in vivo observations ( Figure 5) were due simply to a larger quantity of antibody I in the AbIJI sera than in the AbI sera. Therefore, in the second set of in vivo observations ( Figure 6 ) the quantities of sera were adjusted so that in each series of four observations the quantity of antibody I was constant. Under these conditions the in vivo inhibitory activity of AbIII sera is clearly different from AbI sera.
Discussion
The in vivo activity of these sera corresponds with the in vitro activity. It is likely that the in vivo effects of AbI sera are due to their prevent- Figure. 
